295 related articles for article (PubMed ID: 29673525)
1. Optogenetics and Chemogenetics.
Vlasov K; Van Dort CJ; Solt K
Methods Enzymol; 2018; 603():181-196. PubMed ID: 29673525
[TBL] [Abstract][Full Text] [Related]
2. Optoanesthesia: Use of Anesthetic Photolabels In Vivo.
McKinstry-Wu AR; Kelz MB
Methods Enzymol; 2018; 603():171-180. PubMed ID: 29673524
[TBL] [Abstract][Full Text] [Related]
3. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.
Gomez JL; Bonaventura J; Lesniak W; Mathews WB; Sysa-Shah P; Rodriguez LA; Ellis RJ; Richie CT; Harvey BK; Dannals RF; Pomper MG; Bonci A; Michaelides M
Science; 2017 Aug; 357(6350):503-507. PubMed ID: 28774929
[TBL] [Abstract][Full Text] [Related]
4. Studying brain-regulation of immunity with optogenetics and chemogenetics; A new experimental platform.
Ben-Shaanan T; Schiller M; Rolls A
Brain Behav Immun; 2017 Oct; 65():1-8. PubMed ID: 27890661
[TBL] [Abstract][Full Text] [Related]
5. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
Chen X; Choo H; Huang XP; Yang X; Stone O; Roth BL; Jin J
ACS Chem Neurosci; 2015 Mar; 6(3):476-84. PubMed ID: 25587888
[TBL] [Abstract][Full Text] [Related]
6. Behavioral and Physiological Effects of a Novel Kappa-Opioid Receptor-Based DREADD in Rats.
Marchant NJ; Whitaker LR; Bossert JM; Harvey BK; Hope BT; Kaganovsky K; Adhikary S; Prisinzano TE; Vardy E; Roth BL; Shaham Y
Neuropsychopharmacology; 2016 Jan; 41(2):402-9. PubMed ID: 26019014
[TBL] [Abstract][Full Text] [Related]
7. Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys.
Nagai Y; Miyakawa N; Takuwa H; Hori Y; Oyama K; Ji B; Takahashi M; Huang XP; Slocum ST; DiBerto JF; Xiong Y; Urushihata T; Hirabayashi T; Fujimoto A; Mimura K; English JG; Liu J; Inoue KI; Kumata K; Seki C; Ono M; Shimojo M; Zhang MR; Tomita Y; Nakahara J; Suhara T; Takada M; Higuchi M; Jin J; Roth BL; Minamimoto T
Nat Neurosci; 2020 Sep; 23(9):1157-1167. PubMed ID: 32632286
[TBL] [Abstract][Full Text] [Related]
8. Activation of noradrenergic terminals in the reticular thalamus delays arousal from propofol anesthesia in mice.
Zhang Y; Fu B; Liu C; Yu S; Luo T; Zhang L; Zhou W; Yu T
FASEB J; 2019 Jun; 33(6):7252-7260. PubMed ID: 30860868
[TBL] [Abstract][Full Text] [Related]
9. Resolving Behavioral Output via Chemogenetic Designer Receptors Exclusively Activated by Designer Drugs.
Burnett CJ; Krashes MJ
J Neurosci; 2016 Sep; 36(36):9268-82. PubMed ID: 27605603
[TBL] [Abstract][Full Text] [Related]
10. Advances in optogenetic and chemogenetic methods to study brain circuits in non-human primates.
Galvan A; Caiola MJ; Albaugh DL
J Neural Transm (Vienna); 2018 Mar; 125(3):547-563. PubMed ID: 28238201
[TBL] [Abstract][Full Text] [Related]
11. Optogenetic and chemogenetic therapies for epilepsy.
Walker MC; Kullmann DM
Neuropharmacology; 2020 May; 168():107751. PubMed ID: 31494141
[TBL] [Abstract][Full Text] [Related]
12. Genetic Reporters of Neuronal Activity: c-Fos and G-CaMP6.
Hudson AE
Methods Enzymol; 2018; 603():197-220. PubMed ID: 29673526
[TBL] [Abstract][Full Text] [Related]
13. Designer receptors enhance memory in a mouse model of Down syndrome.
Fortress AM; Hamlett ED; Vazey EM; Aston-Jones G; Cass WA; Boger HA; Granholm AC
J Neurosci; 2015 Jan; 35(4):1343-53. PubMed ID: 25632113
[TBL] [Abstract][Full Text] [Related]
14. Eye-Drops for Activation of DREADDs.
Keenan WT; Fernandez DC; Shumway LJ; Zhao H; Hattar S
Front Neural Circuits; 2017; 11():93. PubMed ID: 29218003
[TBL] [Abstract][Full Text] [Related]
15. Combined Optogenetic and Chemogenetic Control of Neurons.
Berglund K; Tung JK; Higashikubo B; Gross RE; Moore CI; Hochgeschwender U
Methods Mol Biol; 2016; 1408():207-25. PubMed ID: 26965125
[TBL] [Abstract][Full Text] [Related]
16. The use of chemogenetics in behavioural neuroscience: receptor variants, targeting approaches and caveats.
Campbell EJ; Marchant NJ
Br J Pharmacol; 2018 Apr; 175(7):994-1003. PubMed ID: 29338070
[TBL] [Abstract][Full Text] [Related]
17. Chemogenetic manipulation of ventral pallidal neurons impairs acquisition of sign-tracking in rats.
Chang SE; Todd TP; Bucci DJ; Smith KS
Eur J Neurosci; 2015 Dec; 42(12):3105-16. PubMed ID: 26469930
[TBL] [Abstract][Full Text] [Related]
18. The DMCdrive: practical 3D-printable micro-drive system for reliable chronic multi-tetrode recording and optogenetic application in freely behaving rodents.
Kim H; Brünner HS; Carlén M
Sci Rep; 2020 Jul; 10(1):11838. PubMed ID: 32678238
[TBL] [Abstract][Full Text] [Related]
19. Practical Considerations for the Use of DREADD and Other Chemogenetic Receptors to Regulate Neuronal Activity in the Mammalian Brain.
Aldrin-Kirk P; Björklund T
Methods Mol Biol; 2019; 1937():59-87. PubMed ID: 30706390
[TBL] [Abstract][Full Text] [Related]
20. Using opioid receptors to expand the chemogenetic and optogenetic toolbox.
Damez-Werno DM; Kenny PJ
Neuron; 2015 May; 86(4):853-855. PubMed ID: 25996128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
